JERUSALEM--(BUSINESS WIRE)--May. 9, 2013--
BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a biopharmaceutical
development company, announced today that its Chief Executive Officer,
Kinneret Savitsky, Ph.D., and its Chief Financial and Operating Officer,
Philip Serlin, will present at the Oppenheimer 14th Annual Israeli
Conference on Sunday, May 12, 2013, at 12:00 p.m. Israeli local time.
The conference is being held at the David Intercontinental Hotel in Tel
Aviv, Israel.
About BioLineRx
BioLineRx is a publicly-traded
biopharmaceutical development company. BioLineRx is dedicated to
building a portfolio of products for unmet medical needs or with
advantages over currently available therapies. BioLineRx’s current
portfolio consists of seven clinical stage candidates: BL-1040, for
prevention of pathological cardiac remodeling following a myocardial
infarction, which has been out-licensed to Ikaria Inc., is currently
undergoing a pivotal CE-Mark registration trial; BL-5010 for
non-surgical removal of skin lesions has completed a Phase 1/2 study;
BL-7040 for treating inflammatory bowel disease (IBD) has completed a
Phase 2a trial; BL-8040 for treating acute myeloid leukemia (AML) and
other hematological cancers will shortly commence a Phase 2 study;
BL-1021 for neuropathic pain is in Phase 1 development; BL-8020 for
hepatitis C (HCV) has commenced a Phase 1/2 study; and BL-1020 for
schizophrenia. In addition, BioLineRx has five products in various
pre-clinical development stages for a variety of indications, including
central nervous system diseases, infectious diseases, cardiovascular and
autoimmune diseases.
BioLineRx’s business model is based on acquiring molecules mainly from
biotechnological incubators and academic institutions. The Company
performs feasibility assessment studies and development through
pre-clinical and clinical stages, with partial funding from the Israeli
Government’s Office of the Chief Scientist (OCS). The final stage
includes partnering with medium and large pharmaceutical companies for
advanced clinical development (Phase 3) and commercialization. For more
information on BioLineRx, please visit www.biolinerx.com,
the content of which does not form a part of this press release.
Source: BioLineRx Ltd.
KCSA Strategic Communications
Garth Russell, 1-212-896-1250
grussell@kcsa.com
or
Todd
Fromer, 1-212-896-1250
tfromer@kcsa.com
or
Tsipi
Haitovsky, Public Relations
+972-3-6240871
tsipih@netvision.net.il